🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Interesting new frontier for RT in pancreas with MRI guided precision to deliver higher RT dose but remains unclear truly beneficial above standard of care

One of our proudest moments of 2023 was receiving our highest ever ranking in the latest release of the "World’s Best Specialised Hospitals". We were rated 14th out of 300 #oncology hospitals from around the globe. Read more: petermac.org/about-us/news-…

An impressive 55 Peter Mac Cancer Centre researchers have been named in the top 2% of most-cited scientists in the world based on a recently updated study published by Stanford University. The top two per cent includes the top 100,000 most cited scientists! Congratulations. 🥂 petermac.org/about-us/news-…

What an amazing philanthropic effort… a figure we can’t even dream of.

Daring to hope for a pancreatic cancer advance, Michael KC Lee will today be announced as recipient of the Paul Dear Postdoctoral Fellowship - at the #aflhawkscats "Dare to Hope" match. Legacy of the late Hawthorn great Paul Dear. More: petermac.org/about-us/news-…

The next generation of cancer drugs … precision guided bomb against her2 expression and it only requires some expression, not amplified expression. Bystander effect for once is not friendly fire but our friend.

For those interested to hear about the heavy science behind emerging treatment in clinical trial for pancreatic cancer … this is my answer… my hope for pancreatic cancer. Very cool biology but gives me a headache how amazing complicated it is….

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma finance.yahoo.com/news/merck-ann… via Yahoo Finance

‘A crime against cancer knowledge’: World-class Victorian research suffers major budget blow. New from Aisha Dow and I theage.com.au/national/victo…

Yesterday marks a milestone for the last 4 years becoming a clinician scientist and the fruit of my labour hopefully build towards a novel approach in targeting pancreatic cancer. I look forward to participate in recruiting patients to this treatment in the next few months!

💚💚💚ALBERTA AGREES TO COVER PEMAZYRE FOR CHOLANGIOCARCINOMA 🙌🤝💪 #CCAHope #cholangiocarcinoma #Alberta #CancerTreatment #HealthcareVictory #AdvocacyWorks calgary.ctvnews.ca/alberta-agrees…

🧬Cancer types and genes associated with germline mutations 👇 ASCO OncoAlert JCO Precision Oncology #cancer #oncology #genetics #MedX

Finding the Right Partner: Triplet Therapy for 1st line Biliary Tract Cancers @JCO doi.org/10.1200/JCO-24… 👉 SWOG-1815 was 🚫 despite promising phs-2 data 👉 Is there still a role of triplet CTx in BTC? 👉 Downstaging, neoadjuvant? 🧐 Summary of recent trials, food for

Adjuvant chemotherapy compared to observation in resected biliary tract cancers: Survival meta-analysis of phase-III controlled trials European J Cancer doi.org/10.1016/j.ejca… 👉4 trials: BILCAP, ASCOT, BCAT, PRODIGE-12 👉only ASCOT met 1° EP 🧐Not convincing, we need to do

FLOT/TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative GC/GEJ cancer The Lancet Oncology doi.org/10.1016/S1470-… 🔎 PRODIGE 51-FFCD-GASTFOX phs 3 trial 👉ORR 62 vs 53% 👉mPFS 7·59 vs 5·98 mo 👉mOS 15·08 vs 12·65 mo 🧐Intersting option for fit pts

Treatment selection pressure meant that upon progression post Claudin 18.2 targeting ADC that 75% retained some lower expression of 25% or more but is this good enough for another ADC to work? More so it can be toxic is our patients for enough for more ADC?